Podcast #268 · 24 Oct 2025
Non-Muscle Invasive Bladder Cancer: Role of Medical Oncology
- Medical Oncology
- Urologic Oncology
- Non-Muscle Invasive Bladder Cancer (NMIBC)
- BCG-Unresponsive Bladder Cancer
- 2025 NMIBC Creator Weekend™
- Immune Checkpoint Inhibitors
- Cystectomy
- Carcinoma in Situ (CIS)
With the introduction of checkpoint inhibitors into non-muscle invasive bladder cancer (NMIBC) management, who’s on point for planning, administering, and optimizing combination therapies? Is it still the urologist, or does medical oncology play a more significant role now than it did before? In this episode of the BackTable 2025 NMIBC Creator Weekend™ series, host Dr. Bogdana Schmidt sits down with Dr. Tyler Stewart, medical oncologist from the University of California San Diego, to discuss the contemporary role of medical and surgical oncology in treating non-muscle invasive bladder cancer.
This podcast is supported by